Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 767

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 3
Chunk 767
---
 Vander Hoek served as our Chief Financial Officer.

Set
forth below is a description of the background and business experience of our directors and executive officers.

Anatoly
Dritschilo, M.D. Dr. Dritschilo is a co-founder of the Company and has served as Chief Executive Officer and Chairman of the Board
of Directors since the Company’s formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held
multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department
Chair from 1980 to 2022; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2022; Medical Director of
Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005
to 2007. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation
Hospital, and the MedStar Health Research Institute. Previously, he was a founding director of Oncomed, Inc. and a member of the board
of directors of Neopharm, Inc. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National
Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania,
a medical degree from the College of Medicine of New Jersey and residency training from the Harvard Joint Center for Radiation Therapy.
His qualifications support his service as our Chief Executive Officer and Chairman of the Board of Directors.

Timothy
J. Lorber, CPA serves as the Company’s Chief Financial Officer, a position he assumed on a part-time basis commencing June
13, 2024 and assumed the full-time position of Chief Financial Officer on September 9, 2024. Mr. Lorber has more than 40 years of professional
finance experience, including Legg Mason, Inc. (“Legg Mason”), one of the world’s larger public global asset management
firms, where he worked from March 2006 to July 2020 serving in various finance leadership roles, including Managing Director and Chief
Accounting Officer until its sale in 2020. From August 2021 until June 2024, Mr. Lorber has served in leadership roles with several privately
held businesses, overseeing finance,